Immunoprophylactic strategies against respiratory influenza virus infection.
The objective of this report is to evaluate the prophylactic efficacy of liposome-mediated immunotherapy for prevention of respiratory influenza virus infection in mice. Antiviral antibody, interferon-gamma and poly (ICLC) were encapsulated in liposomes and they were evaluated for their ability to induce protective immunity against lethal influenza infection. Passive immunization using liposome-encapsulated antiviral antibody was found to offer complete protection against the virus challenge. However, this pretreatment must be administered within 24 h prior to virus challenge to be protective. Pretreatment with liposome-encapsulated interferon-gamma was found to stimulate cellular immune responses, but the protection is partial. Immunoprophylaxis using liposome-encapsulated double-stranded (ds) RNA poly (ICLC) provided complete and longer-lasting protection against influenza infection. These results suggest liposome-mediated immunoprophylactic approaches are effective in the prevention of respiratory influenza virus infection.
Chemical and Biological Defence Section, Defence Research Establishment Suffield, Box 4000 Station Main, Alberta, T1A 8K6, Medicine Hat, Canada.
E G
EG
Saravolac
D
D
Sabuda
C
C
Crist
K
K
Blasetti
G
G
Schnell
H
H
Yang
M
M
Kende
H B
HB
Levy
J P
JP
Wong
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000281:Administration, Intranasal; D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage; D006801:Humans; D007116:Immunization, Passive / Q000379:methods*; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D007371:Interferon-gamma / Q000008:administration & dosage; D008081:Liposomes; D051379:Mice; D011070:Poly I-C / Q000008:administration & dosage; D011994:Recombinant Proteins; D013997:Time Factors
D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D008081:Liposomes; D011994:Recombinant Proteins; D007371:Interferon-gamma; D011070:Poly I-C